Transgenic zebrafish embryos to evaluate the in vivo effects of different liposome-paclitaxel nanocarrier system

Abstract Zebrafish is an established valuable model for understanding the complex in vivo behavior of systemic nanocarrier strategies, their safety profile, and the array of possible compositions. To date, we have explored the possibility of Paclitaxel (PTX) delivery using liposome systems as a prom...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrea Persico, Laura Molteni, Paride Mantecca, Marcelo Kravicz, Cinzia Bragato
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-00258-1
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849705062704611328
author Andrea Persico
Laura Molteni
Paride Mantecca
Marcelo Kravicz
Cinzia Bragato
author_facet Andrea Persico
Laura Molteni
Paride Mantecca
Marcelo Kravicz
Cinzia Bragato
author_sort Andrea Persico
collection DOAJ
description Abstract Zebrafish is an established valuable model for understanding the complex in vivo behavior of systemic nanocarrier strategies, their safety profile, and the array of possible compositions. To date, we have explored the possibility of Paclitaxel (PTX) delivery using liposome systems as a promising approach to treating cancer. Despite its benefits, this efficacious anti-cancer drug presents a main adverse effect, such as the onset of chemotherapy-induced peripheral neuropathy (CIPN). Thus, many research efforts are aimed at searching for the resolution or reduction of such problems. Taking advantage of zebrafish embryos, a powerful model for predicting and translating what is observed in humans, we investigated the plain PTX outcomes and compared them to the effects of different liposomes loaded with PTX. Since approximately 70% of human genes have at least one orthologue in zebrafish, studying the molecular mechanisms underlying chemotherapy-induced toxicity and increased oxidative stress becomes easy. First, we used a transgenic model to evaluate the systemic response to different concentrations of PTX, planning the final concentration to be loaded in liposomes, with and without functionalization. Then, we assessed the effects of this promising nanocarrier system at a molecular, histochemical, and behavioral level in reducing the detrimental side effects of the most successful cancer drug.
format Article
id doaj-art-ffeb02e4fe2340689a0ba744e03371ce
institution DOAJ
issn 2045-2322
language English
publishDate 2025-05-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-ffeb02e4fe2340689a0ba744e03371ce2025-08-20T03:16:34ZengNature PortfolioScientific Reports2045-23222025-05-0115111510.1038/s41598-025-00258-1Transgenic zebrafish embryos to evaluate the in vivo effects of different liposome-paclitaxel nanocarrier systemAndrea Persico0Laura Molteni1Paride Mantecca2Marcelo Kravicz3Cinzia Bragato4POLARIS Research Center, Department of Earth and Environmental Sciences, University of Milano-BicoccaExperimental Neurology Unit, School of Medicine and Surgery, University of Milano-BicoccaPOLARIS Research Center, Department of Earth and Environmental Sciences, University of Milano-BicoccaSchool of Medicine and Surgery, University of Milano-BicoccaPOLARIS Research Center, Department of Earth and Environmental Sciences, University of Milano-BicoccaAbstract Zebrafish is an established valuable model for understanding the complex in vivo behavior of systemic nanocarrier strategies, their safety profile, and the array of possible compositions. To date, we have explored the possibility of Paclitaxel (PTX) delivery using liposome systems as a promising approach to treating cancer. Despite its benefits, this efficacious anti-cancer drug presents a main adverse effect, such as the onset of chemotherapy-induced peripheral neuropathy (CIPN). Thus, many research efforts are aimed at searching for the resolution or reduction of such problems. Taking advantage of zebrafish embryos, a powerful model for predicting and translating what is observed in humans, we investigated the plain PTX outcomes and compared them to the effects of different liposomes loaded with PTX. Since approximately 70% of human genes have at least one orthologue in zebrafish, studying the molecular mechanisms underlying chemotherapy-induced toxicity and increased oxidative stress becomes easy. First, we used a transgenic model to evaluate the systemic response to different concentrations of PTX, planning the final concentration to be loaded in liposomes, with and without functionalization. Then, we assessed the effects of this promising nanocarrier system at a molecular, histochemical, and behavioral level in reducing the detrimental side effects of the most successful cancer drug.https://doi.org/10.1038/s41598-025-00258-1Transgenic zebrafish embryosLiposome nanocarrier systemPaclitaxelTherapeutic strategy
spellingShingle Andrea Persico
Laura Molteni
Paride Mantecca
Marcelo Kravicz
Cinzia Bragato
Transgenic zebrafish embryos to evaluate the in vivo effects of different liposome-paclitaxel nanocarrier system
Scientific Reports
Transgenic zebrafish embryos
Liposome nanocarrier system
Paclitaxel
Therapeutic strategy
title Transgenic zebrafish embryos to evaluate the in vivo effects of different liposome-paclitaxel nanocarrier system
title_full Transgenic zebrafish embryos to evaluate the in vivo effects of different liposome-paclitaxel nanocarrier system
title_fullStr Transgenic zebrafish embryos to evaluate the in vivo effects of different liposome-paclitaxel nanocarrier system
title_full_unstemmed Transgenic zebrafish embryos to evaluate the in vivo effects of different liposome-paclitaxel nanocarrier system
title_short Transgenic zebrafish embryos to evaluate the in vivo effects of different liposome-paclitaxel nanocarrier system
title_sort transgenic zebrafish embryos to evaluate the in vivo effects of different liposome paclitaxel nanocarrier system
topic Transgenic zebrafish embryos
Liposome nanocarrier system
Paclitaxel
Therapeutic strategy
url https://doi.org/10.1038/s41598-025-00258-1
work_keys_str_mv AT andreapersico transgeniczebrafishembryostoevaluatetheinvivoeffectsofdifferentliposomepaclitaxelnanocarriersystem
AT lauramolteni transgeniczebrafishembryostoevaluatetheinvivoeffectsofdifferentliposomepaclitaxelnanocarriersystem
AT paridemantecca transgeniczebrafishembryostoevaluatetheinvivoeffectsofdifferentliposomepaclitaxelnanocarriersystem
AT marcelokravicz transgeniczebrafishembryostoevaluatetheinvivoeffectsofdifferentliposomepaclitaxelnanocarriersystem
AT cinziabragato transgeniczebrafishembryostoevaluatetheinvivoeffectsofdifferentliposomepaclitaxelnanocarriersystem